TLDR Moderna shares plunged 24.56% despite positive Phase III melanoma trial results. Jefferies models $54 billion in global peak sales for Moderna’s cancer therapy. The melanoma study met recurrence-free and distant metastasis-free endpoints. Jefferies raised Moderna’s price tar...